{"podcast":{"title":"EP Edge Journal Watch: Cardiac Electrophysiology Research","slug":"ep-edge-journal-watch-7561379","podcast_index_feed_id":7561379,"rss_url":"https://feeds.transistor.fm/ep-edge-journal-watch","website_url":null,"image_url":"https://img.transistorcdn.com/KWuXQ6fPAArQRCgfrqrxfzQNWh_DnAU4t75wkubUSk4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jMzFi/ZTYxOTI1M2U4NGRj/OGZmZjBhMDFlMjFm/NDQwMC5wbmc.jpg","author":"Niraj Sharma","episode_count":45,"summary":"Welcome to EP Edge Journal Watch, where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this weekly podcast distills high-impact cardiovascular and Cardiac Electrophysiology and arrhythmia research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology, arrhythmias analysis A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve","last_synced_at":"2026-09-14T18:19:31.787966+00:00","page_url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379"},"episode":{"title":"EP Edge® Journal Watch 36: ESC 2026, AF Ablation and Sham Trials | PVI-SHAM-AF, PFA-SHAM, SHAM-PVI, FlexPulse, NEXAF, IDEAL-AF, ENRICH-AF","slug":"ep-edge-journal-watch-36-esc-2026-af-ablation-and-sham-trials-pvi-sham-af-pfa-sham-sham-pvi-flexpulse-nexaf-ideal-af-enrich-af","published_at":"2026-09-14T09:30:00+00:00","page_url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-36-esc-2026-af-ablation-and-sham-trials-pvi-sham-af-pfa-sham-sham-pvi-flexpulse-nexaf-ideal-af-enrich-af","show_page_url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379","url":"https://share.transistor.fm/s/403cc123","audio_url":"https://media.transistor.fm/403cc123/f539143d.mp3","summary":"What defines successful atrial fibrillation ablation: fewer recurrences, lower AF burden, better quality of life, or all three? In this ESC Congress 2026 special issue of EP Edge Journal Watch, Dr. Sharma examines evidence from Munich, Germany, August 28–31, 2026, alongside previously covered sham-controlled trials to explore what meaningful patient benefit should look like. PVI-SHAM-AF leads the discussion. Rolf Wachter and colleagues found lower sampled atrial fibrillation burden after catheter ablation, but no demonstrated superiority over sham on the primary Atrial Fibrillation Effect on Quality-of-Life (AFEQT) endpoint. We examine the primary result, the favorable sensitivity analysis, and why failure to demonstrate superiority does not establish equivalence. PFA-SHAM and SHAM-PVI provide the earlier evidence. These trials demonstrated additional patient-reported benefit with pulsed field ablation and cryoballoon pulmonary vein isolation, respectively. Their differing populations, endpoint priorities, and monitoring methods help frame the comparison, without implying that one ablation technology is superior to another. Our In Depth synthesis examines baseline symptom severity, possible ceiling effects, recruitment, cardioversion, antiarrhythmic management, beta blockers, and continuous versus intermittent rhythm monitoring. These are potential contributors to the discordant findings, not established explanations. Drawing on Andrea Natale’s review, the Marrouche–Glotzer editorial, and Dulai’s SHAM-PVI substudy, we distinguish rhythm recurrence from residual burden, symptoms, functional improvement, and treatment burden. What should count as clinical success, and which definitions still need prospective validation? FlexPulse follows with 12-month results for focal d…","meta_description":"What defines successful atrial fibrillation ablation: fewer recurrences, lower AF burden, better quality of life, or all three? In this ESC Congress 2026…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1877,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/ep-edge-journal-watch-36-esc-2026-af-ablation-and-sham-trials-pvi-sham-af-pfa-sham-sham-pvi-flexpulse-nexaf-ideal-af-enrich-af/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-36-esc-2026-af-ablation-and-sham-trials-pvi-sham-af-pfa-sham-sham-pvi-flexpulse-nexaf-ideal-af-enrich-af.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}